Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer
Muller, P. A. J.
Creamer, D. P. M.
Bittar, M. N.
AffiliationSchool of Science, Engineering and Environment, University of Salford, Cockcroft Building 305, Manchester M5 4WT, UK
MetadataShow full item record
AbstractMutations in the p53 tumor suppressor are found in over 50% of cancers. p53 function is controlled through posttranslational modifications and cofactor interactions. In this study, we investigated the posttranslationally modified p53, including p53 acetylated at lysine 382 (K382), p53 phosphorylated at serine 46 (S46), and the p53 cofactor TTC5/STRAP (Tetratricopeptide repeat domain 5/ Stress-responsive activator of p300-TTC5) proteins in lung cancer. Immunohistochemical (IHC) analysis of lung cancer tissues from 250 patients was carried out and the results were correlated with clinicopathological features. Significant associations between total or modified p53 with a higher grade of the tumour and shorter overall survival (OS) probability were detected, suggesting that mutant and/or modified p53 acts as an oncoprotein in these patients. Acetylated at K382 p53 was predominantly nuclear in some samples and cytoplasmic in others. The localization of the K382 acetylated p53 was significantly associated with the gender and grade of the disease. The TTC5 protein levels were significantly associated with the grade, tumor size, and node involvement in a complex manner. SIRT1 expression was evaluated in 50 lung cancer patients and significant positive correlation was found with p53 S46 intensity, whereas negative TTC5 staining was associated with SIRT1 expression. Furthermore, p53 protein levels showed positive association with poor OS, whereas TTC5 protein levels showed positive association with better OS outcome. Overall, our results indicate that an analysis of p53 modified versions together with TTC5 expression, upon testing on a larger sample size of patients, could serve as useful prognostic factors or drug targets for lung cancer treatment.
CitationAlhebshi H, Tian K, Patnaik L, Taylor R, Bezecny P, Hall C, et al. Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer. International Journal of Molecular Sciences. 2021;22(24):14.
JournalInt J Mol Sci
- TTC5 is required to prevent apoptosis of acute myeloid leukemia stem cells.
- Authors: Lynch JT, Somerville TD, Spencer GJ, Huang X, Somervaille TC
- Issue date: 2013 Apr 4
- TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
- Authors: Yu L, Xiao Y, Zhou X, Wang J, Chen S, Peng T, Zhu X
- Issue date: 2019 Dec
- Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
- Authors: Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, Zhu WG
- Issue date: 2006 Apr
- Human TTC5, a novel tetratricopeptide repeat domain containing gene, activates p53 and inhibits AP-1 pathway.
- Authors: Xiong Y, Wang L, Deng W, Wang J, Shi T
- Issue date: 2013 Nov
- Regulation of glucocorticoid receptor activity by a stress responsive transcriptional cofactor.
- Authors: Davies L, Paraskevopoulou E, Sadeq M, Symeou C, Pantelidou C, Demonacos C, Krstic-Demonacos M
- Issue date: 2011 Jan